Regeneron Reports Interim Data from P-III (C-POST) Trial of Libtayo Adjuvant to Treat High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Shots:

• The P-III (C-POST) trial assessed Libtayo adj. (n=205; 350mg, IV, Q3W for first 12wks. followed by 700mg, IV, Q6W for 36wks.) vs PBO (n=204) to treat high-risk CSCC patients (N=415) for ~48wks.
• Study met its first prespecified interim analysis, showing 68% reduced disease occurrence & death risk at 24mos. median follow-up, with additional follow-up, incl. OS analysis (2EP) underway; AEs occurred in 91% vs 89% (grade ≥3 AEs: 24% vs 14%). The US FDA’s filing is expected in H1’25
• Libtayo is a fully human mAb developed using Regeneron’s VelocImmune tech that inhibits the PD-1 pathway in cancer cells to suppress T-cell activation for treating advanced BCC, CSCC, NSCLC & cervical cancer

Ref: Regeneron  | Image: Regeneron

Related News:- Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com